Longeveron Announces Private Placement of up to $30 Million
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) entered a private placement expected to raise up to $30 million in gross proceeds, with an initial closing of approximately $15 million priced at-the-market under Nasdaq rules.
Initial proceeds fund operations into 4Q2026, past anticipated pivotal Phase 2b ELPIS II HLHS topline data in 3Q2026. The financing includes Class A shares and Series A non-voting convertible preferred shares convertible at $0.52, and a contingent second tranche tied to trial milestones and share price.
Positive
- $15M initial gross proceeds secured
- Up to $30M total funding contingent on milestones
- Proceeds extend cash runway into 4Q2026
- Preferred shares immediately convertible at $0.52 per share
Negative
- Immediate dilution: conversion equates to 22,832,770 common shares
- Second tranche depends on trial results and share price
- 50% interest sale of future Rare Pediatric Disease PRV proceeds reduces upside
News Market Reaction – LGVN
On the day this news was published, LGVN gained 68.27%, reflecting a significant positive market reaction. Argus tracked a peak move of +87.7% during that session. Our momentum scanner triggered 60 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $24.74M at that time. Trading volume was exceptionally heavy at 222.8x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LGVN was up 9.49% pre-news context while 3 Argus-listed biotech peers also moved up (median 4.1%), suggesting a sector-wide bid alongside this company-specific financing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Clinical trial data | Positive | -5.6% | Phase 2b frailty data showed significant 6MWT improvement vs placebo. |
| Feb 13 | Executive leadership | Positive | +3.0% | Appointment of Stephen H. Willard as CEO and focus on HLHS data. |
| Feb 05 | Policy and designations | Positive | -5.3% | Reauthorization of Rare Pediatric Disease PRV and HLHS designations. |
| Jan 29 | IP / patent | Positive | -2.4% | Japan patent grant for MSC potency assay, extending IP to 2041. |
| Jan 26 | FDA interaction | Positive | +6.2% | FDA Type C meeting granted ahead of pivotal ELPIS II HLHS data. |
Recent positive clinical, regulatory, and corporate updates often saw mixed or negative next-day price reactions, indicating a history of divergences between news tone and price moves.
Over recent months, LGVN reported multiple milestones around laromestrocel and HLHS, including a Phase 2b frailty trial publication, FDA Type C meeting, and Japan patent protection through 2041. It also highlighted ELPIS II enrollment of 40 pediatric patients at 12 centers and governance changes such as a new CEO. Today’s private placement aligns with prior disclosures emphasizing the pivotal Phase 2b ELPIS II readout expected in Q3 2026 and the need to fund ongoing clinical and regulatory work.
Market Pulse Summary
The stock surged +68.3% in the session following this news. A strong positive reaction aligns with the company securing up to $30 million in funding at-the-market, which it expects to extend cash runway into 4Q26, beyond the pivotal Phase 2b ELPIS II HLHS topline readout in 3Q26. However, the structure involves common and convertible preferred shares totaling tens of millions of potential new shares, so past patterns of mixed post-news performance and dilution sensitivity could influence how durable such a move becomes.
Key Terms
private placement financial
Hypoplastic Left Heart Syndrome (HLHS) medical
Series A Non-Voting Convertible Preferred Stock financial
Rare Pediatric Disease Priority Review Voucher regulatory
registration statement regulatory
registration rights agreement financial
Phase 2b medical
AI-generated analysis. Not financial advice.
$15 million upfront with a milestone-driven potential additional$15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules- Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused funds
- Initial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout
MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it has entered into a definitive agreement with certain institutional and accredited investors for up to approximately
The private placement is led by Coastlands Capital, with participation from Janus Henderson Investors, along with Logos Capital and Kalehua Capital, for total gross proceeds in the initial closing of approximately
H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.
At the initial closing, the Company will issue 6,013,384 shares of its Class A common stock at a purchase price of
Additionally, at the initial closing, the Company has agreed to sell to the investors an interest in
The Company intends to use the net proceeds from the financing, together with its existing cash and cash equivalents, for funding for its ongoing clinical and regulatory development of laromestrocel, working capital and other general corporate purposes. Based on current operating plans, the Company expects that its cash and cash equivalents, excluding the net proceeds from the closing of the second tranche, will fund operations into the fourth quarter of 2026.
The initial closing of the private placement is expected to occur on or about March 11, 2026, subject to satisfaction of customary closing conditions.
The offer and sale of the foregoing securities is being made in a private placement pursuant to an exemption under the Securities Act of 1933, as amended (the “Securities Act”), and the securities have not been registered under the Securities Act or applicable state securities laws. The securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. Concurrently with the execution of the definitive agreements, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of Class A common stock and shares of Class A common stock underlying the Preferred Shares issuable upon conversion thereof following the closing of each tranche.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Forward Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. These include, but are not limited to, statements regarding completion of the private placement financing, the satisfaction of customary closing conditions related to the private placement financing, the anticipated use of proceeds therefrom, the conversion of the Series A Preferred Stock, the future possible receipt of a Rare Pediatric Disease Priority Review Voucher from the U.S. FDA, the achievement of certain milestone conditions related to clinical study results for the Company’s laromestrocel program for HLHS, the possible occurrence of a second closing for the private placement financing, and statements regarding the various below-listed factors. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the timing and completion of the private placement, including the milestone-driven closing, the use of the net proceeds from the private placement, our ability to achieve anticipated milestones, the timing of any of our interactions with the FDA, our cash runway, any receipt of a PRV by us, the future restoration of executive compensation levels; our intention and ability to repay certain compensation amounts to executives or rehire employees currently furloughed; the grant of certain equity awards; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
